31.35
+0.51(+1.65%)
Currency In USD
| Previous Close | 30.84 |
| Open | 30.84 |
| Day High | 31.44 |
| Day Low | 30.42 |
| 52-Week High | 40.28 |
| 52-Week Low | 25.53 |
| Volume | 269,808 |
| Average Volume | 628,654 |
| Market Cap | 1.75B |
| PE | 23.75 |
| EPS | 1.32 |
| Moving Average 50 Days | 32.73 |
| Moving Average 200 Days | 33.88 |
| Change | 0.51 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $2,402.3 as of April 25, 2025 at a share price of $31.35. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $1,601.12 as of April 25, 2025 at a share price of $31.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
GlobeNewswire Inc.
Apr 23, 2025 9:14 PM GMT
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today annou
Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Mar 04, 2025 9:30 PM GMT
ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced t
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 27, 2025 1:30 PM GMT
ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to